We recommend Monocef-SB instead of Oframax Forte. Exact salt composition from top brand
100% Same
Salt CompositionEffectivenessStrength
Top Branded
Substitute
Salt Composition in bothCeftriaxone 500mg + Sulbactam 250mg
Salt CompositionCeftriaxone 500mg + Sulbactam 250mg (same for both)
Oframax Forte 500 mg/250 mg Injection
You Searched
Oframax Forte 500 mg/250 mg Injection
Sun Pharmaceutical Industries Ltd.
Oframax Forte 500 mg/250 mg Injection
Sun Pharmaceutical Industries Ltd.
₹89
Our Recommendation
Monocef SB 500/250mg Injection 1s
Aristo Pharmaceuticals Pvt. Ltd.
1,500+ Customers trust this
WHO GMP Certified
Assured by
Assured
Monocef SB 500/250mg Injection 1s
Assured by
Assured
1,500+ trust this
WHO GMP Certified
Customers also bought
More About Oframax Forte
Benefits
In Bacterial infections Oframax Forte 500 mg/250 mg Injection contains two different medicines, Ceftriaxone and Sulbactum, that work together to kill the bacteria that cause infections. Ceftriaxone works by stopping the growth of bacteria. Sulbactam reduces resistance and enhances the activity of Ceftriaxone against bacteria. Oframax Forte 500 mg/250 mg Injection can be used to treat many different bacterial infections such as ear, sinus, throat, lung, urinary tract, skin and soft tissues. This medicine usually makes you feel better within a few days, but you should continue taking it as prescribed even when you feel better to make sure that all bacteria are killed and do not become resistant.
Side Effects
The majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you're worried about them.
How to use
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How it works
Oframax Forte 500 mg/250 mg Injection is a combination of two medicines: Ceftriaxone and Sulbactam. Ceftriaxone is an antibiotic. It works by preventing the formation of the bacterial protective covering which is essential for the survival of bacteria. Sulbactam is a beta-lactamase inhibitor which reduces resistance and enhances the activity of Ceftriaxone against bacteria.
Safe: No harmful side effects are associated with consuming alcohol alongside Oframax Forte 500 mg/250 mg Injection
Safe when prescribed by an expert: Oframax Forte 500 mg/250 mg Injection is generally considered safe to use during pregnancy. Animal studies have shown low or no adverse effects to the developing baby; however, there are limited human studies.
Caution Advised: Oframax Forte 500 mg/250 mg Injection should be used with caution during breastfeeding. Breastfeeding should be held until the treatment of the mother is completed and the drug is eliminated from her body.
Not Safe: Oframax Forte 500 mg/250 mg Injection may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Seek medical advice from your doctor: There is limited information available on the use of Oframax Forte 500 mg/250 mg Injection in patients with kidney disease. Doctor consultation is advised.
Caution Advised: Oframax Forte 500 mg/250 mg Injection should be used with caution in patients with severe liver disease. Dose adjustment of Oframax Forte 500 mg/250 mg Injection may be needed. Doctor consultation is advised. Dose adjustment of Oframax Forte 500 mg/250 mg Injection is not recommended in patients with mild to moderate liver disease.
What if I forget to take it?
If a dose of Oframax Forte 500 mg/250 mg Injection is missed, it's advisable to consult your doctor.
Manufacturer Address
Plot no 107/108,Namli block , Ranipool, East Sikkim 737135
Disclaimer
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
